The Staphylococcus aureus Network Adaptive Platform Trial is an innovative trial to evaluate a range of interventions with the aim of improving outcomes for patients with Staphylococcus aureus bacteraemia (AKA bloodstream infections).
While we have effective antibiotic treatments for S.aureus bloodstream infections, it is not known which of these are the best. There are only a few published studies that compare current available treatments and, fewer than 3,000 participants combined have ever been enrolled in published randomised controlled trials for treatments of S. aureus bloodstream infection. SNAP is a whole-of-life trial and includes both paediatric and adult participants.
There are currently four parts to the study, which we call ‘domains’. To find out more about each of these, please watch the videos below:
• Antibiotic backbone domain
• Adjunctive treatment domain (Study completed in October 2025)
• Early Oral Switch domain
• PET/CT domain
Subscribe to receive email updates about SNAP and the study results.
Professor Joshua S Davis PhD, FRACP, MBBS (Hons), DTM&H, Grad Cert Pop Health. Infectious Diseases Physician and NHMRC Career Development Fellow at the University of Newcastle and the Menzies School of Health Research.
Professor Steven YC Tong PhD, FRACP, MBBS (Hons), Grad Dip Epidemiol Biostats, Infectious Diseases Physician with the Victorian Infectious Diseases Service.
We are pleased to share the November issue of the SNAP Trial Global Newsletter.
The SNAP trial includes all age groups because people of all ages.
A summary of how Staphylococcus aureus and penicillin have been instrumental in both the success and failure of one another since they met. Carly Botheras (PhD Candidate, Geelong Centre for Emerging Infectious Diseases, Barwon Health)
